A Long-Term Baseline for the First Person to Reverse Age-Related Vision Loss

The beginning of a long life he gave his first patient a medicine to cure a real problem due to old age.

Life Biosciences is testing its ER-100 drug, which the company says he is vision restored in monkeys, due to safety and its effects on the study of 18 adults next year.

It will be looking at patients with glaucoma and NAION, two conditions that cause damage to the vital cells in the optic nerve, which transmits information from the back of the eye to the brain. ER-100 is designed to regenerate the cells to function and restore vision.

It is the first cell therapy using this technology to receive FDA approval to enter human clinical trials, the first opportunity to test whether the technology “can reduce human disease,” according to Life Biosciences co-founder David Sinclair, who is also a professor of genetics at Harvard Medical School.

The biology of aging – understanding how cells and body functions deteriorate over time – is here the root of longevity science. ER-100 is the focus of the entire biosphere for its ability to reverse cellular aging. Life Biosciences, based in Boston, says it is developing its technology to treat many diseases related to aging in various organs, such as. fatty liver disease.

“Our research has shown that aging is driven primarily by the loss of epigenetic information, rather than irreversible damage. This clinical study represents the first opportunity to test whether restoring this information can reduce human disease,” said Sinclair.